Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Tegileridine plus intercostal nerve block for pain after thoracoscopic lung removal

Official title: Study on the Analgesic Effect of Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection

Run by Tongji Hospital · NCT07386626 · Data updated 2026-11-12

This trial will test whether giving a local intercostal nerve block together with patient-controlled tegileridine improves pain control for adults having thoracoscopic lobectomy or segmentectomy.

More Lobectomy trials

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment118 (estimated)
SponsorTongji Hospital
Academic / other
Locations1 site (Wuhan, Hubei)
StatusRecruiting
StartedMarch 18, 2026
Main results expectedDecember 31, 2026
Study endsJanuary 31, 2027
Registry record updatedApril 8, 2026
Trial IDNCT07386626 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–75 undergoing elective thoracoscopic lobectomy or segmentectomy with ASA I–III and BMI 18–30 who can give informed consent are the intended participants.

Probably not a fit

Patients who are pregnant or breastfeeding, have severe respiratory or cardiovascular disease, severe liver or kidney dysfunction, sleep apnea, opioid dependence, allergies to study drugs, or other major contraindications are excluded and unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center interventional study at Tongji Hospital combines an early intercostal nerve block (ICNB) with patient-controlled intravenous tegileridine to cover both immediate incision pain and later central/visceral pain after thoracoscopic lung resection. Patients receive perioperative ICNB and postoperative patient-controlled analgesia with tegileridine, with interventions listed to include sufentanil as a comparator or reference analgesic. The approach aims to provide rapid incision analgesia from the block and sustained central analgesia from tegileridine while reducing common opioid side effects. Primary outcomes will focus on postoperative pain scores, opioid consumption, recovery metrics, and incidence of chronic post-surgical pain.

Why it matters

Potential benefit: If successful, the combination could give faster and more stable pain relief after thoracoscopic lung surgery, speed recovery, reduce opioid side effects, and lower the risk of chronic post-surgical pain.

How similar studies have gone: Multimodal approaches that combine regional nerve blocks with systemic analgesics have previously reduced acute pain and opioid use after thoracic surgery, although tegileridine itself is less widely studied than standard opioids.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age range: 18 to 75 years old;
* Patients undergoing elective thoracoscopic lobectomy or segmentectomy;
* ASA classification levels I-III;
* BMI 18 \~ 30 kg/m2。
* Voluntarily participate and sign an informed consent form.

Exclusion Criteria:

* Patients with preoperative alcohol dependence and long-term use of analgesic drugs are receiving analgesic treatment for other acute and chronic pain;
* Pregnant or lactating women;
* Allergies or other contraindications to the anesthetics, analgesics, and antiemetic drugs used in the study;
* Patients with severe sleep apnea syndrome or acute or severe bronchial asthma;
* Suffering from mental and neurological disorders or cognitive impairment, known or suspected gastrointestinal obstruction, severe liver and kidney dysfunction (Child Pugh score C), chronic obstructive pulmonary disease or severe cardiovascular disease, etc;
* Researchers consider participants who are not suitable to participate in this study and those who refuse to participate.

Where it's running

  • Tongji hospital
    Wuhan, Hubei, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.